SEC 13F Intelligence

Managers / Q2 2020 · view latest →

Centerbridge Partners, L.P.

CIK 0001484836 · 375 PARK AVENUE, 11TH FLOOR, NEW YORK, NY, 10152 · 212 672 5000

Reported Value
$468M
Q2 2020
Positions
33
Filings on Record
33
2019–present window
Filed
Aug 14, 2020
original filing

Summary

Centerbridge Partners, L.P. reported $468M in U.S.-listed holdings across 33 positions for Q2 2020.

The portfolio is heavily concentrated: American Renal Assocs alone accounts for 24.5% of reported value.

Compared with Q1 2020, the fund opened 2 new positions and exited 2.

Portfolio Metrics

Turnover
+8.5%
vs prior filed quarter
Top-10 Concentration
+96.9%
share of reported value
Largest Position
+24.5%
American Renal Assocs
New / Exited
2 / 2
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $982MQ4 ’18Q1 ’19: $729MQ2 ’19: $815MQ3 ’19: $550MQ4 ’19: $618MQ4 ’19Q1 ’20: $412MQ2 ’20: $468MQ3 ’20: $894MQ4 ’20: $1.2BQ4 ’20Q1 ’21: $1.1BQ2 ’21: $1.1BQ3 ’21: $856MQ4 ’21: $1.8BQ4 ’21Q1 ’22: $1.6BQ2 ’22: $1.1BQ3 ’22: $875MQ4 ’22: $1.0BQ4 ’22Q1 ’23: $1.0BQ2 ’23: $642MQ3 ’23: $467MQ4 ’23: $604MQ4 ’23Q1 ’24: $623MQ2 ’24: $505MQ3 ’24: $478MQ4 ’24: $468MQ4 ’24Q1 ’25: $510MQ2 ’25: $434MQ3 ’25: $101MQ4 ’25: $59MQ4 ’25Q1 ’26: $61Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 77.2%Unit: 7.7%REIT: 5.0%ETP: 4.3%US DOMESTIC: 4.3%Other: 1.5%
  • Common Stock · 77.2% · $361M
  • Unit · 7.7% · $36M
  • REIT · 5.0% · $23M
  • ETP · 4.3% · $20M
  • US DOMESTIC · 4.3% · $20M
  • Other · 1.5% · $7M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AVBAVALONBAY CMNTYS INCNEW+150.0K150.0K+$23M$23M
REALOGY HLDGS CORPNEW+100.0K100.0K+$741,000$741,000
EXTENDED STAY AMER INCADDED+2.43M3.24M+$30M$36M
BLACKSTONE MTG TR INCADDED+11.40M17.91M+$12M$17M
GNWGENWORTH FINL INCSOLD OUT−1.54M0−$5M$0
UNITI GROUP INCSOLD OUT−500.0K0−$3M$0
TEVATEVA PHARMACEUTICAL INDS LTDTRIMMED−580.0K100.0K−$5M$1M
ENSCO JERSEY FIN LTDTRIMMED−34.50M16.83M−$11M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2020

16 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AMERICAN RENAL ASSOCS HLDGSCOM24.54%$115M17.62M
2PCGPG&E CORPhistory →COM16.01%$75M8.45M
3GNKGENCO SHIPPING & TRADING LTDhistory →SHS14.07%$66M10.49M
4HGVHILTON GRAND VACATIONS INChistory →COM12.82%$60M3.07M
5EXTENDED STAY AMER INCUNIT 99/99/9999B7.74%$36M3.24M
6FOCUS FINL PARTNERS INCCOM CL A6.37%$30M901.8K
7AVBAVALONBAY CMNTYS INChistory →COM4.96%$23M150.0K
8ISHARES TRIBOXX INV CP ETF4.31%$20M150.0K
9BLACKSTONE MTG TR INCNOTE 4.375% 5/0 · NOTE 4.750% 3/13.83%$18M19.15M
10SGRYSURGERY PARTNERS INChistory →COM2.27%$11M919.2K
11CYHCOMMUNITY HEALTH SYS INC NEWhistory →COM1.09%$5M1.70M
12MALLINCKRODT PUB LTD COSHS0.67%$3M1.17M
13ENSCO JERSEY FIN LTDNOTE 3.000% 1/30.47%$2M16.83M
14ENDO INTL PLCSHS0.44%$2M600.0K
15TEVATEVA PHARMACEUTICAL INDS LTDSPONSORED ADS0.26%$1M100.0K
16REALOGY HLDGS CORPCOM0.16%$741,000100.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$61M3May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$59M2Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$101M4Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$434M9Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$510M11May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$468M13Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$478M15Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$505M17Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$623M20May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$604M20Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$467M25Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$642M27Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$1.0B29May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.0B34Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$875M62Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.1B67Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.6B71May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.8B111Feb 17, 2022RESTATEMENTchanges · EDGAR ↗
Q3 2021$856M108Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B124Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.1B109May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.2B36Feb 23, 2021RESTATEMENTchanges · EDGAR ↗
Q3 2020$894M23Nov 17, 202013F-HRchanges · EDGAR ↗
Q2 2020$468M33Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$412M40May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$618M17Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$550M22Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$815M20Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$729M26May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$982M37Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 9 additional managers.

  • Centerbridge Credit Advisors, L.L.C.028-13862
  • Centerbridge Partners Holdings, LLC028-13861
  • Aronson Jeffrey028-13858
  • Gallogly Mark T028-13857
  • Centerbridge Special Credit Advisors, L.L.C.028-14395
  • Centerbridge Advisors, LLC028-15424
  • Centerbridge Special Credit Advisors II, L.L.C028-16779
  • Centerbridge Special Credit Advisors III, L.L.C.028-19382
  • Centerbridge Advisors II, LLC028-20085

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.